Funding & Deals
Sep 02, 2026 · 1 min read · 6,319 views
BridgeBio oncology spinout to go public via combination with SPAC from Cormorant and Bihua Chen
I
Isabella Hart
Editorial · Sep 02, 2026
Reports indicate that the second blank-check vehicle from Cormorant's Bihua Chen plans to take BridgeBio's oncology spinout onto the Nasdaq. The special purpose acquisition company - known as Helix
← Previous
Innovent declares Phase 3 success for gastric cancer ADC that attracted huge Takeda deal
Next →
Replimune melanoma drug snags coveted FDA approval after yearlong clash, two rejections
